Our customer contact center is currently experiencing high call volumes. We thank you for your patience.
High call volume
Our customer contact center is currently experiencing high call volumes. We thank you for your patience.
The Food and Drug Administration (FDA) recently approved biosimilar products that can be utilized in place of reference drugs in most clinical circumstances. Biosimilar products offer additional safe and cost-effective options. The FDA approved several biosimilars for Remicade® (infliximab) including Infliximab(unbranded Remicade).
Remicade and its biosimilar products, Infliximab (unbranded Remicade),infliximab-dyyb (Inflectra®), infliximab-abda (Renflexis®)and infliximab-axxq (AvsolaTM) are part of the BCBSND Infliximab medical policy.
Disregard previous Renflexis (infliximab-abda) change
Blue Cross Blue Shield of North Dakota (BCBSND) is no longer moving forward with changing Renflexis to a non-preferred agent on April, 1, 2022. Members may continue to receive Renflexis without making therapy changes if they have a current prior approval. BCBSND will contact members for awareness. Members whose Renflexis (Q5104) prior approval dates were adjusted will receive a letter with their new approval dates.